Coronary artery bypass graft (CABG) surgery is the revascularization procedure of choice to treat patients with acute coronary syndromes (ACS) in whom coronary anatomy is not suitable for percutaneous coronary intervention. In CABG patients, subsequent ischemic events may originate in either grafts or in the native coronary artery. Asymptomatic graft occlusion occurs in up to 40% of patients within 1 year (symptomatic occlusion occurs in 3.4% of patients) and is associated with a mortality rate of up to 9% (1) (2) (3) . Graft thrombosis is thought to be the leading mechanism of graft closure, and platelet activation may play a key role in both early and late graft occlusion (4) (5) (6) (7) (8) . Aspirin improves early vein graft patency and ischemic outcomes, although significant aspirin resistance has been reported after CABG surgery, whereas its effect on long-term patency remains uncertain (9) (10) (11) (12) . Additional platelet inhibition through the P2Y 12 receptor with clopidogrel in patients undergoing CABG after ACS was associated with reduced ischemic rates, but concerns regarding operative bleeding risk require preoperative discontinuation and have hindered widespread adoption in the management of ACS patients undergoing CABG (13) (14) (15) (16) (17) (18) . Consequently, there is a lack of consensus regarding both clopidogrel use post-CABG and opportunities for novel therapeutic agents to fill the treatment gap in non-ST-segment elevation (NSTE) ACS patients undergoing CABG.
Thrombin generation increases during CABG surgery and persists afterward, potentially increasing the risk of thrombotic complications, including graft and native coronary artery thrombosis (19, 20) . Therefore, the blockade of the main platelet thrombin receptor, the protease-activated receptor (PAR)-1, could be a more specific strategy to reduce graft occlusion and native coronary thrombosis after CABG, thus preventing subsequent ischemic events. Vorapaxar (Merck, Whitehouse Station, New Jersey) is a selective, competitive, oral PAR-1 antagonist Whellan et al. March 25, 2014 March 25, :1048 Vorapaxar in ACS Patients Undergoing CABG that inhibits thrombin-mediated platelet activation (21) . In addition, in animal models, vorapaxar analogues did not increase surgical bleeding (22) . In the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, among patients with NSTE ACS, vorapaxar did not significantly reduce a quintuple endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization, but it was associated with a reduction in the composite of CV death, MI, and stroke, largely due to a reduction of MI (23) . Similarly, in a study of patients with chronic atherosclerotic disease, the rates of death, MI, and stroke were significantly reduced by vorapaxar (24) . In both trials, vorapaxar was associated with a significant increase in major bleeding. We undertook a pre-specified analysis to assess the efficacy and safety of vorapaxar in TRACER patients undergoing CABG.
Methods
The analysis population includes patients who were randomized in the TRACER trial (n ¼ 12,944), for which the primary results and study design have been published (23, 25) . Briefly, patients were enrolled if they presented with acute symptoms of coronary ischemia within 24 h before hospital presentation and with at least 1 of the following: cardiac troponin (I or T) or creatine kinase-myocardial band levels higher than the upper limit of normal, new ST-segment depression >0.1 mV, or transient ST-segment elevation (<30 min) of >0.1 mV in 2 contiguous leads. Patients were randomly assigned in a 1:1 ratio to receive vorapaxar (40-mg loading dose and 2.5-mg daily maintenance dose thereafter) or matching placebo with stratification according to intention to use a glycoprotein IIb/IIIa inhibitor (vs. none) and intention to use a parenteral direct thrombin inhibitor (vs. other antithrombins).
This analysis included patients who underwent CABG during index hospitalization after they were randomized and began the study drug. Because time to CABG may vary across centers, and because it may be local practice to discharge patients and then schedule CABG, we performed an additional analysis to include all CABG surgeries performed within 30 days of randomization.
The study protocol recommended that the study drug be continued during CABG. Temporary interruptions were defined as any disruption in study drug 2 days, but then resumed. Permanent discontinuation was definitive premature interruption of study treatment. For the efficacy endpoints, the accrual period was from CABG to the date of site notification of study termination. The endpoints for this analysis were: 1) the composite of CV death, MI, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization (primary); and 2) the composite of CV death, MI, or stroke (secondary) from the TRACER study.
For bleeding endpoints, the accrual period was from CABG to the last dose of randomized treatment. The CABG-related major bleeding was defined according to the Thrombolysis In Myocardial Infarction (TIMI) criteria and was pre-specified as part of the TRACER trial event definition. To provide further detail, CABG-related major bleeding was defined as any hemorrhage meeting any of the following criteria: 1) fatal bleeding (i.e., bleeding that directly results in death); 2) perioperative intracranial bleeding; 3) reoperation after closure of the sternotomy incision to control bleeding; 4) transfusion of 5 U of whole blood or packed red blood cells within 48 h; or 5) chest tube output >2 l within 24 h. All efficacy and bleeding events in the TRACER study were systematically adjudicated by a central clinical events committee. All bleeding events were classified according to the TIMI and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) scales.
Associations between treatment assignments and outcomes were assessed using time-to-event analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression modeling, with the adjustment of randomization stratification factors and baseline covariates. Event rates were estimated by the Kaplan-Meier method. To test interaction, because patients had to be classified as either "CABG" or "no CABG" within a common time point (discharge from the index event), the event accrual period was from discharge to site notification. A sensitivity analysis was also carried out by including all events since randomization and accounting for propensity of having CABG.
The SAS version 9.3 (SAS Institute, Cary, North Carolina) was used to perform statistical analyses. The p values were not adjusted for multiple comparisons. The TRACER study was approved by an institutional review committee, and all patients gave informed consent.
Results
Baseline characteristics. In total, 1,312 (10.1%) of 12,944 patients enrolled in the TRACER trial underwent CABG surgery during the index hospitalization (vorapaxar n ¼ 639; placebo n ¼ 673). There were 1,510 patients who underwent CABG within 30 days of randomization (vorapaxar n ¼ 750; placebo n ¼ 760). The overall study population was followed for a median of 502 days (interquartile range [IQR] : 349 to 667 days). The 2 treatments arms were well balanced regarding baseline characteristics for patients undergoing CABG (Table 1) . Study treatment and concomitant antiplatelet agents. The median time to CABG in patients treated with vorapaxar was 120 h (IQR: 47 to 194 h) and with placebo was 119 h (IQR: 48 to 214 h) ( Table 2 ). At randomization, there was a lower utilization of thienopyridine in patients later undergoing CABG (72% CABG vs. 89% no CABG), although use was similar between the vorapaxar and placebo groups. Before CABG, the study drug was interrupted in 23% of placebo patients and in 26% of vorapaxar patients. Among those who had the treatment withheld before surgery, the median time from last dose to CABG was 6 days (IQR: 4 to 8 days) for placebo and vorapaxar patients.
In those who underwent CABG, 39% in the placebo group and 38% in the vorapaxar group received clopidogrel within 5 days of CABG. Clopidogrel at discharge was used in 16% of placebo patients and in 19% of vorapaxar patients, which was much lower than among non-CABG patients (84.3% placebo; 84.9% vorapaxar). Efficacy of vorapaxar in CABG patients. In patients undergoing CABG during index hospitalization (n ¼ 1,312), (Fig. 1 ). All components of the primary endpoint were numerically lower with vorapaxar. When all patients who underwent CABG in the first 30 days after randomization were included, the effect on post-CABG events remained consistent, with a 48% reduction with vorapaxar (HR: 0.52; 95% CI: 0.36 to 0.76; p ¼ 0.001), and the interaction between CABG and vorapaxar treatment effect on postdischarge events remained significant with groups defined at 30 days (p ¼ 0.028).
Vorapaxar was also associated with lower occurrence of the key secondary endpoint (43 events; 2-year Kaplan- Among those who discontinued the randomized drug throughout CABG, TIMI major CABG-related bleeding occurred in 9 (7.3%) placebo patients and in 13 (9.3%) vorapaxar patients. Reoperation for bleeding in this subgroup was similar between the vorapaxar (n ¼ 7 [5.0%]) and placebo (n ¼ 7 [5.6%]) groups, and in the group of patients who continued the drug through the perioperative period (vorapaxar: n ¼ 23 [4.6%]; placebo: n ¼ 24 [4.4%] ). In patients There was a mild excess in chest tube drainage in patients treated with vorapaxar versus placebo at 8 h (350 ml vs. 308 ml), at 24 h (635 ml vs. 580 ml), and total (830 ml vs. 780 ml).
When all CABG surgeries performed during the first 30 days from randomization were included, the results for CABG-related major bleeding were similar (Table 4) . Bleeding after discharge. In patients who underwent CABG during index hospitalization, bleeding after discharge increased with vorapaxar (Table 5 ). In the CABG population, GUSTO moderate or severe bleeding at 2 years was 4.0% with vorapaxar and 2.2% with placebo (HR: 1.60; 95% CI: 0.75 to 3.42). The TIMI major bleeding was infrequent in the CABG cohort, but increased with vorapaxar (2-year Kaplan-Meier rates of 1.4% with vorapaxar and 0.8% with placebo; HR: 1.83; 95% CI: 0.54 to 6.26). In the CABG cohort, there was 1 patient (0.2%) with intracranial hemorrhage who received vorapaxar and no intracranial hemorrhage with placebo. In the non-CABG population, the GUSTO moderate or severe bleeding rate at 2 years was 4.1% with vorapaxar and 2.8% with placebo (HR: 1.38; 95% CI: 1.09 to 1.75). There was no statistically significant interaction (p ¼ 0.75).
Discussion
In the TRACER study patients who underwent CABG, we observed that adding vorapaxar versus placebo to standardof-care practices reduced the occurrence of the primary endpoint with an estimated relative hazard reduction of 45%. The improvement in the primary endpoint postdischarge for patients randomized to vorapaxar and undergoing CABG during index hospitalization appeared to be much stronger than that observed in the non-CABG cohort, a finding supported by a statistically significant interaction. In the CABG cohort, vorapaxar was also associated with a 34% reduction of CV death, MI, or stroke (a larger estimated effect than in the main TRACER study cohort), although the interaction was not statistically significant. There was a nonsignificant numerical increase in surgical bleeding with vorapaxar without increased occurrence of reoperations for bleeding. There was also an increase in non-CABG bleeding, which is consistent with the main results of the TRACER trial.
These results suggest that PAR-1 antagonism may be a viable therapeutic option to reduce recurrent ischemic events post-CABG. All components of the primary endpoint, including mortality, were numerically lower with vorapaxar after CABG, and the efficacy of vorapaxar seemed overall enhanced post-CABG. It is possible that PAR-1 activation is an important mechanism leading to graft failure. Particularly, increased thrombin generation after CABG may induce a higher susceptibility to the action of PAR-1 antagonists (26,27). Concomitant Whellan et al. March 25, 2014 March 25, :1048 Vorapaxar in ACS Patients Undergoing CABG antiplatelet therapy might have also played a role. In fact, consistent with registry data, use of clopidogrel at discharge was much lower in CABG patients than in non-CABG patients (18% vs. 85%, respectively). It is possible that the effect of vorapaxar is stronger when added to aspirin only versus when added to aspirin and clopidogrel as triple oral antiplatelet therapy. It is interesting that vorapaxar was associated with a numerical reduction of urgent revascularization (not associated with an MI) in CABG patients, but not in non-CABG patients. Vorapaxar may affect the mechanism leading to urgent revascularization in CABG patients (e.g., graft failure), but not in non-CABG patients 
(e.g., in-stent restenosis, progression of pre-existing stenosis).
The use of antiplatelet therapy in addition to aspirin therapy is controversial due to the increased risk of bleeding that undermines the reduction in clinical events. In the CURE (Clopidogrel in Unstable angina to prevent Recurrent ischemic Events) trial (14) , the reduction of CV death, MI, or stroke in the CABG cohort was consistent with the main CURE trial results. However, available evidence is controversial concerning a benefit in adding clopidogrel post-CABG to improve vein graft patency and CV events (28) (29) (30) . Ticagrelor, a reversibly binding, directacting oral P2Y 12 receptor antagonist, was associated with a 16% reduction in CV death, MI, or stroke, which was consistent overall with the main trial results, although ticagrelor appeared to have a more robust effect on mortality in the CABG cohort (15, 16) . The CABG bleeding rates were increased and comparable for both ticagrelor and clopidogrel (15, 18) . Based on these results, guidelines recommend withholding either ticagrelor or clopidogrel 5 days prior to CABG surgery (31) . A third P2Y 12 antagonist, prasugrel (vs. clopidogrel), was associated with significantly reduced mortality after adjusting for pre-operative risk in the few patients participating in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) trial who underwent follow-up CABG surgery (32) . However, prasugrel requires an even longer interruption (7 days) before surgery, and the improved clinical outcomes with prasugrel need to be weighed against the substantial increased risk of CABG-related bleeding. In contrast, vorapaxar (or matching placebo) was to be continued perioperatively, as recommended by the TRACER study protocol.
In contrast with the main TRACER study results, in which there was a significant increase in major bleeding with vorapaxar, the perioperative safety profile of vorapaxar seemed acceptable in this analysis. In patients who received vorapaxar, there was a numerical increase in major CABGrelated bleeding that did not meet statistical significance, a modest increase in chest tube drainage, and no trend indicating increased rates of reoperation to control bleeding. It is important to note that most CABG procedures were performed while vorapaxar was still active, unlike current recommendations for P2Y 12 antagonists. In fact, 75% of patients in the vorapaxar group did not have interruption in study treatment before CABG. In addition, because the effect of duration of a single dose of vorapaxar is 2 to 3 weeks and the median time to CABG was only 120 h, even when the study drug was interrupted, it was still expected to be within its biological activity time frame. Our results confirm: 1) earlier findings that show no increase in surgical bleeding in an animal model with a vorapaxar analogue; and 2) preliminary results among 76 patients undergoing CABG in the phase II study, in which vorapaxar did not increase surgical bleeding (33) . Overall, these data suggest the possibility of using vorapaxar during the perioperative period. The contrast between surgical and spontaneous bleeding effects of vorapaxar observed in this analysis could be related to different roles of PARs under different pathophysiologic circumstances.
It is possible that, during surgery, a high concentration of thrombin can increase activity of the PAR-4 receptordwhich, in humans, requires higher concentrations 
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Whellan et al. March 25, 2014 March 25, :1048 Vorapaxar in ACS Patients Undergoing CABG of thrombin to be activated than PAR-1 doesdtherefore creating a "rescue" mechanism (34). Alternatively, thrombin generation during cardiopulmonary bypass surgery may cause platelet activation that leads to the desensitization of platelets and a reduction of platelet reactivity. By reducing perioperative, thrombin-mediated platelet activation, vorapaxar may prevent desensitization of platelets. Finally, it is possible that the PAR-1 receptor may have a more limited role in normal hemostasis after major vessel injury (35) . Future analysis to also assess the safety of vorapaxar in the setting of noncardiac surgery will be helpful to further define how PAR-1 antagonism could be tolerated in the setting of surgical procedures. The effect of vorapaxar on bleeding events (mostly representing spontaneous bleeding) after discharge in CABG patients is largely consistent with the overall TRACER study results, particularly in terms of a relative increase in bleeding. However, it is noteworthy that the absolute risk of bleeding is lower in CABG patients than in non-CABG patients, possibly due to the selection of candidates who undergo surgery and the lower concomitant use of clopidogrel. Therefore, the trade-off between efficacy and bleeding may be favorable to vorapaxar use in CABG patients, if the results of the present analysis are confirmed in a prospective randomized clinical trial. Study limitations. Because the current analysis is not a randomized comparison of vorapaxar and placebo, the results have no immediate applicability in clinical practice and should be interpreted as hypothesis-generating. This is a pre-specified analysis of a post-randomization subgroup within a large clinical trial. Thus, we cannot rule out that study participation and study drug assignment may have influenced the choice of candidates for CABG, or that factors other than CABG itself may have influenced the results. It is important to note, however, that this was a double-blinded study and the time to CABG was short, so it is unlikely that there is bias of CABG referral based on treatment assignment. The vorapaxar and placebo groups were well balanced in the CABG and the non-CABG cohorts regarding baseline demographics. However, unmeasured confounders cannot be excluded with certainty.
Because the primary focus of the TRACER trial was not the evaluation of vorapaxar in patients undergoing CABG, data that may have improved our understanding of the underlying mechanism supporting these resultsdincluding the reason for patient referral to CABG, method for harvesting vein grafts, use of cardiopulmonary bypass circuit, or post-operative imaging of vein graftsdwere not collected as part of the analysis (36, 37) . In particular, we did not collect imaging to assess graft failure; therefore, we are unable to provide a mechanistic explanation in support of the observed effect.
The CABG group represents 10% of the overall study population, and the study was not stratified by CABG. Some of the results and lack of statistical significance may have been influenced by insufficient power. No adjustment for multiple comparisons was performed so as not to reduce sensitivity in generating hypotheses.
Conclusions
In a large, nonrandomized cohort of patients with NSTE ACS who participated in the TRACER trial and subsequently underwent CABG, we have observed a marked reduction in the primary endpoint among patients assigned to vorapaxar and enhanced efficacy in comparison with the
